Rujun Xu
Impact in
-
- Cancer-related molecular mechanisms research
Papers in
- Oncology 12
- Cancer-related Molecular Pathways 3
-
- RNA modifications and cancer 4
- Protein Degradation and Inhibitors 3
- Histone Deacetylase Inhibitors Research 3
- Cancer-related gene regulation 3
- Co-authors
- Liuzhi Zhou (2 shared papers)Guangchao Zhuo (3 shared papers)Lu Yin (1 shared paper)Honghe Zhang (2 shared papers)Shirong Zhang (6 shared papers)Shenglin Ma (2 shared papers)Zhijian Yu (1 shared paper)Wei Li (1 shared paper)
- Journals
- Medical Oncology (4 papers)European Journal of Medicinal Chemistry (3 papers)Acta Pharmacologica Sinica (2 papers)Frontiers in Molecular Biosciences (2 papers)Molecular Cancer Therapeutics (1 paper)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Rujun Xu
33 papers receiving 335 citations
Peers
Comparison fields: 5 of 64
- Cancer Research 113
- Oncology 103
- Pulmonary and Respiratory Medicine 95
- Pharmacology 44
- Pharmacology 20
Countries citing papers authored by Rujun Xu
This map shows the geographic impact of Rujun Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rujun Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rujun Xu more than expected).
Fields of papers citing papers by Rujun Xu
This network shows the impact of papers produced by Rujun Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rujun Xu. The network helps show where Rujun Xu may publish in the future.
Co-authors
The 25 scholars most cited alongside Rujun Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 37 | |
| 2 | 2016 | 32 | |
| 3 | 2021 | 23 | |
| 4 | 2008 | 23 | |
| 5 | 2005 | 22 | |
| 6 | Expression of type IV collagen, metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in laryngeal squamous cell carcinomas. | 2011 | 21 |
| 7 | 2020 | 17 | |
| 8 | 2021 | 15 | |
| 9 | 2009 | 15 | |
| 10 | 2016 | 13 | |
| 11 | 2007 | 13 | |
| 12 | 2022 | 11 | |
| 13 | 2006 | 11 | |
| 14 | 2023 | 10 | |
| 15 | 2022 | 10 | |
| 16 | 2020 | 9 | |
| 17 | 2023 | 9 | |
| 18 | 2016 | 9 | |
| 19 | 2018 | 7 | |
| 20 | 2022 | 6 |
About Rujun Xu
Rujun Xu is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Pharmacology, having authored 35 papers that have together received 340 indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (5 papers), RNA modifications and cancer (4 papers), Estrogen and related hormone effects (4 papers), Protein Degradation and Inhibitors (3 papers), Cancer, Lipids, and Metabolism (3 papers), Histone Deacetylase Inhibitors Research (3 papers), Cancer-related Molecular Pathways (3 papers) and Cancer-related gene regulation (3 papers). The work is most often cited by research in Cancer Research (113 citations), Oncology (103 citations), Pulmonary and Respiratory Medicine (95 citations), Pharmacology (44 citations) and Pharmacology (20 citations). Rujun Xu has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Liuzhi Zhou, Guangchao Zhuo, Lu Yin, Honghe Zhang, Shirong Zhang, Shenglin Ma, Zhijian Yu, Wei Li, Guangdi Chen and Zhong‐Sheng Zhao. Their work appears in journals such as Medical Oncology, European Journal of Medicinal Chemistry, Acta Pharmacologica Sinica, Frontiers in Molecular Biosciences and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.